Evidence Based Cataract

Company snapshot

Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lupus Nephritis, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. NovaPharmaNews links 10 clinical program(s), 0 drug profile(s), and 10 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 1 (4), approved (1).

• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Evidence Based Cataract. Not investment advice.

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  Hospital Authority

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Evidence Based Cataract.

1. Jun 8, 2026 Clinical update

   Clopidogrel — Approved

2. Jun 8, 2026 Clinical update

   cyclophosphamide — Phase 1

3. Jun 5, 2026 Clinical update

   WT1-sensitized T cells — Phase 1

4. Jun 5, 2026 Clinical update

   Tabelecleucel — Phase 2

5. Jun 5, 2026 Clinical update

   EBV-specific T cells (EBV-CTLs) — Phase 2

View all clinical trial activity →

• What is Evidence Based Cataract?

  Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lupus Nephritis, Relapsed/Refractory B-cell Non-Hodgkin Lymphom

• Is Evidence Based Cataract publicly traded?

  Evidence Based Cataract appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Evidence Based Cataract develop or market?

  We link 8 drug profile(s) where Evidence Based Cataract is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/atara-biotherapeutics#company-drugs.

• What are the latest developments for Evidence Based Cataract?

  In the last 12 months our linked public records show 10 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Evidence Based Cataract focus on?

  Evidence Based Cataract focuses on EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis based on our analysis of their pipeline programs and drug development activities.